CEPI | News, Hiring, Layoffs, Competitors, CEO, Fundraising Insights
CEPI, the Coalition for Epidemic Preparedness Innovations, is a global partnership established in 2017 to accelerate the development...
CEPI, the Coalition for Epidemic Preparedness Innovations, is a global partnership established in 2017 to accelerate the development of vaccines against future epidemics. It focuses on developing vaccines for various pathogens, including Ebola, Lassa virus, and COVID-19, and aims to compress vaccine development timelines to 100 days. CEPI also invests in platform technologies for rapid vaccine development and ensures fair allocation of vaccines worldwide through initiatives like COVAX.
Website
Size
51-200 employees
Industry
Research Services
Specialities
Epidemic Preparedness, Vaccine Development, Vaccine, Health, Science
🛍️ CEPI Product and Pricing News →
👔 CEPI CEO, Management and Leadership Team →
⚔️ CEPI Alternatives and Competitors →
💼 CEPI Hiring and Layoffs →
🤖 CEPI Developer, Integration and Automation News →
📈 CEPI Financials, Fundraising and Valuation News →
🛍️ CEPI Product and Pricing News
- In 2024, CEPI expanded its manufacturing network to India and Brazil and initiated Phase 2 clinical trials for a Lassa fever vaccine.
- CEPI is establishing vaccine safety benchmarking in Africa specifically for African vaccines.
- CEPI is supporting new research with the University of Oxford and scientists in Kenya and Tanzania to assess Chikungunya disease burden in East Africa.
- CEPI played a critical role in organizing and funding the Ebola vaccine clinical study 'Tujiokowe' in the Democratic Republic of the Congo, collaborating with partners like LSHTM and Wellcome Trust.
- Nicole Lurie, executive director at CEPI, expressed concern over the lack of epidemiologic data and surveillance.
- CEPI launched 'The Viral Most Wanted Series' to educate about viral families and their pandemic risks.
- Nicole Lurie, executive director at CEPI, expressed concern over the lack of epidemiologic data and surveillance regarding the bird flu outbreak.
- Dr. Rebecca Farkas from CEPI will present at the 20th Annual Non-Dilutive Funding Summit on January 15, 2025, in San Francisco.
👔 CEPI CEO, Management and Leadership Team
⚔️ CEPI Alternatives and Competitors
- Gavi, the Vaccine Alliance |
- The Global Fund |
- International Vaccine Institute (IVI) |
- Bill & Melinda Gates Foundation |
- PATH |
- World Health Organization |
- IAVI
💼 CEPI Hiring and Layoffs
- CEPI is seeking an Executive Director of People & Organisation to lead HR initiatives and support its mission to reduce epidemic risks.
- Dr. Sall has joined CEPI in a new role, as announced by the Global Virus Network on December 10.
- Dr Sall will lead CEPI's manufacturing and supply chain strategy to improve global epidemic and pandemic preparedness by increasing manufacturing capacity in underserved regions.
- Sarah Roberts has left CEPI as the Head of R&D Events & Admin in the United Kingdom to join CityZen Property Management LTD as the Client Accounts & Contract Compliance Manager.
- Dr. Amadou Alpha Sall has been appointed as Executive Director of Manufacturing and Supply Chain at CEPI.
- CEPI is currently hiring for the position of Senior Information Technology Architect in Norway.
- CEPI is currently seeking a Senior Portfolio Manager in Norway.
- Dr. Ankur Mutreja, previously Head of Global South Partnerships at CEPI, has been appointed as Senior Advisor at SMi Systems.
🤖 CEPI Developer, Integration and Automation News
- CEPI signed strategic agreements with Bio-Manguinhos to expand technological capabilities focusing on RNA and viral vector platforms.
- CEPI's CEO, Dr. Richard Hatchett, announced a new collaboration to enhance regional health security and ensure affordable doses for local populations.
- CEPI announced a partnership with Aspen Pharma to produce vaccines in Africa.
- CEPI has partnered with Accumulus Synergy to enhance information equity and accelerate vaccine access by supporting a regulatory collaboration platform with $19.1 million in funding.
📈 CEPI Financials, Fundraising and Valuation News
- CEPI is funding a $9.9 million vaccine safety project in Africa led by the Global Vaccine Data Network to study adverse events in African populations.
- CEPI has funded Abera Bioscience for the development of mucosal vaccines.
- CEPI is funding the development of rapid response platforms and mRNA vaccines for 'Disease X' and has invested in Jurata Thin Film Inc. to produce needle-free vaccine wafers.
- CEPI has committed up to $101 million to support advanced development of three chikungunya vaccine candidates, including Valneva's, which is the first to receive approval from a strict regulatory authority.
- CEPI is funding up to $10.3 million for the ACHIEVE study on chikungunya over three years.
- CEPI is providing up to USD 40 million in initial funding to support SK bioscience's joint R&D project for mRNA vaccine development.
- CEPI is giving £2.16 million to UK CPI to advance the University of Toronto's MANGO device for automating Virus-Like Particle manufacturing.
- CEPI is investing over $100 million in Nipah virus research, supporting vaccine development and collaborating with institutions in Bangladesh and Malaysia to enhance understanding of the virus.
People also viewed
- Amber Beverage Group |
- OpsLevel |
- Groglass |
- General Atlantic |
- Moodify |
- Pryor Learning |
- CBT Nuggets |
- ACI Learning |
- Lorman
